Rafael J. Zamora

Rafael J. Zamora

Auto-generated profile, based on publicly available information

Rafael J. Zamora

Medicus, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2026 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
LCLaura Castro-Labrador
Laura Castro-Labrador
RZRafael Zamora
Rafael Zamora
SSSergio Szyldergemajn
Sergio Szyldergemajn
PCPablo Gómez del Campo
Pablo Gómez del Campo
JIJosé Del Castillo Izquierdo
José Del Castillo Izquierdo
Carlos María GalmariniCarlos María Galmarini
Carlos María Galmarini
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) shows marked clinical heterogeneity and poor long-term survival, highlighting the need for simple and reliable risk stratification tools beyond the limited usability of existing complex prognostic models. In this study, we developed and validated PROGRESS (Prostate Cancer Global Risk Evaluation and Stratification Score), a simplified prognostic score derived through machine learning‑guided feature selection distilled into a simple laboratory-based tool. Methods: Baseline data from 2,035 patients with mCRPC (training set) were embedded into synthetic representations, reduced with UMAP, and clustered with DBSCAN to discover outcome-related subpopulations. Feature contribution analysis informed a multivariable model that yielded three independent predictors (prostate specific antigen [PSA], alkaline phosphatase [ALP], and AST) composing PROGRESS. External validation used two independent data sets (n = 1,239) across different therapeutic settings. Overall survival (OS) was analyzed with Kaplan-Meier and Cox regression; discrimination was assessed by ROC-AUC, AUC(t), and Harrel C-index. Results: Unsupervised modeling identified two patient risk subpopulations with significantly different OS rates (median 27.4 v 17.7 months; hazard ratio [HR], 2.20 [95% CI, 1.91 to 2.54]; P < .00001). The three retained predictors (PSA, ALP, and AST) were combined into a composite score (PROGRESS) that showed strong discrimination in the training cohort (ROC-AUC 0.89; AUC(t) 0.60; Harrel C-index 0.69). Using a prespecified cutoff, patients classified by PROGRESS as increased risk had significantly shorter survival than low-risk patients (median 18.3 v 25.6 months; HR, 1.72 [95% CI, 1.50 to 1.97]; P < .0001). PROGRESS prognostic performance was consistent across all validation cohorts (all P < .0001). Conclusion: By combining ML-based pattern discovery with classical modeling, PROGRESS provides a simple, objective, and readily implementable prognostic tool using three inexpensive routine laboratory measures. Its consistent performance across independent data sets supports clinical utility for individual risk stratification, trial enrichment, and early decision making. Prospective real-world validation is warranted.

1 May 2022 in Current Problems in Cardiology
Verified
Journal Article
Closed access
RZRafael J. Zamora
Rafael J. Zamora
EPEduardo Roque Perna
Eduardo Roque Perna
LPLisandro Pereyra
Lisandro Pereyra
DCDiego Caruso
Diego Caruso
MEMaría E. Esquerro
María E. Esquerro
MMMatias Manzotti
Matias Manzotti